The long-term effects of atromid on serum cholesterol

  • Andrew Heffebnan
  • Noel J. Hickey
  • Rlsteárd Mulcahy


Forty-two patients were treated with ‘Atromid’ during a three year period. The initial dose was 2.0g. daily in 40 patients and 1.5g. daily in 2 patients.


  1. 1.
    FitzGerald, O., Mulcahy, R., Fennelly, J. J. and Heffernan, A. (1960). “Serum lipid studies and nicotinic acid therapy”,Lancet, 1, 877.CrossRefGoogle Scholar
  2. 2.
    FitzGerald, O., Heffernan, A., Brennan, P., Mulcahy, R., Fennelly, J. J. and McFarlane, R. (1964). “Effect of nicotinic acid on abnormal serum lipids”,Brit. Med. J., i, 157.CrossRefGoogle Scholar
  3. 3.
    FitzGerald, O., Heffernan, A., Brennan, P., Mulcahy, R. and McFarlane, R. (1963). “Triparanol (Mer-29) in hypercholesterolemia: A double-blind study”,J. Irish Med. Ass., 53, 116.Google Scholar
  4. 4.
    Zak, B. (1957). “Simple rapid microtechnic for serum total cholesterol”,Amer. J. Clin. Path., 27, 583.Google Scholar
  5. 5.
    Oliver, M. F. (1962). “Reduction of serum lipid and uric acid by an orally active androsterone”,Lancet, i, 1323.Google Scholar
  6. 6.
    Hellman, L., Zumoff, B., Kessler, G., Rosenfeld, R. S. and Gallagher, T. F. (1962). “Reduction of serum cholesterol in man by an oral androsterone preparation”,J. Clin. Invest., 41, 1364.Google Scholar
  7. 7.
    Mishkel, M. A. (1964). “The treatment of xanthomatosis with ‘Atromid’”,Med. J. Aust., 2, 828.PubMedGoogle Scholar
  8. 8.
    Hellman, L., Zumoff, B., Kessler, G., Kara, E., Rubin, I. Z. and Rosenfeld, R. S. (1963). “Reduction of cholesterol and lipids in man by ethyl-p-chlorophenoxy-isobutyrate”,Ann. intern. Med., 59, 477.PubMedCrossRefGoogle Scholar
  9. 9.
    Jepson, E. M. and James, D. C. O. (1963). “The treatment of hypercholesterolaemic xanthomatosis with ‘Atromid’”,J. Atherosclerosis. Res., 3, 554.CrossRefGoogle Scholar
  10. 10.
    Denborourh, M. A., Lovell, R. R. H. and Trevaks, K. (1963). “The effect of chlorophenoxyisobutyrate acid ester with androsterone on plasma lipids in women”,Med. J. Aust., 1, 499.Google Scholar
  11. 11.
    Green, K. G., Inman, W.H. W. and Thorp, J. M. (1963). “ Multicentre trial of a mixture of ethyl chlorophenoxyisobutyrate and androsterone (‘Atromid’) in the United Kingdom and Ireland: A preliminary report”,J. Atherocsler. Res., 3, 593.CrossRefGoogle Scholar
  12. 12.
    Peak, H. J., Mitchell, A. S. and Jose, A. D. (1965). “Control of hypercholesterolaemia with ‘Atromid’: A two-year evaluation”,Med. J. Aust., 52, II, 192.Google Scholar
  13. 13.
    Wahlin, R., Cramer, K. and Hood, B. (1964). “Medikamentell behandling vid essentiell hyperlipemi och essentiell hypercholesterolemi (Klinisk prövning av ‘Atromid’)”,Svenska Läkartidn., 61, 802.Google Scholar
  14. 14.
    Carlson, L. A., Högstedt, B. and Orö, L. (1963). “Effect of ‘Atromid’ on plasma lipids and lipoproteins in subjects with hyperlipoproteinemia”,J. Atheroseler. Res., 3, 467.CrossRefGoogle Scholar
  15. 15.
    Martt, J. M. and Lee, G. B. (1965). “Effect of chlorophenoxyisobutyrate on serum lipids”,Circulation, 32, 4, II, 144.Google Scholar
  16. 16.
    Duarte Mantilla, G., Torner Soler, M., Garcia Terradellas, I., Balagner Vintro, L. and Gibert Queraltó (1963). “Accion del ‘Atromid’ sobre las dislipemias en la cardiopatia coronaria”. Read to Congra de Cardioangiol., Alicante.Google Scholar
  17. 17.
    Laubinger, G. (1984). “Erste erfahrungen mit clofibrate bei der behandlung der hypercholesterinämic”,Fortschr. Med., 82, 783.Google Scholar
  18. 18.
    Wagener, J. and Frosch, B. (1964). “Bahandlung von lipid stoffwechselstörungen mit äthyl-β-p-chlorphenoxyisobutyrat”,Med. Klin., 59, 1872PubMedGoogle Scholar

Copyright information

© Springer 1966

Authors and Affiliations

  • Andrew Heffebnan
    • 1
  • Noel J. Hickey
    • 1
  • Rlsteárd Mulcahy
    • 1
  1. 1.Department of CardiologySt. Vincent’s HospitalDublin

Personalised recommendations